Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Pharming Group (NASDAQ:PHAR) saw unusually-high trading volume on Wednesday . Approximately 7,607 shares were traded during trading, an increase of 42% from the previous session’s volume of 5,358 shares.The stock last traded at $8.86 and had previously closed at $9.00.

Analysts Set New Price Targets

PHAR has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group started coverage on shares of Pharming Group in a research report on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock. Finally, Oppenheimer reduced their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th.

Pharming Group Trading Down 0.5 %

The company has a 50-day moving average of $9.09 and a two-hundred day moving average of $8.44. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.